A Clinical Trial of Antiplatelets in Psoriasis

Starting soon · Phase 4 · Has a placebo group

Conditions studied: Psoriasis (PsO), Psoriatic Arthritis (PsA)

In brief

The purpose of this study is to determine the effect of antiplatelet therapy on the endovascular phenotype in psoriasis, specifically whether clopidogrel reduces vascular endothelial pro-atherosclerotic transcript expression more than aspirin or placebo. The primary endpoint is mean change in a composite endothelial pro-inflammatory/pro-atherosclerotic transcript expression signature measured from brachial vein endothelial cells.

Key facts

Study ID

NCT07744191

Run by

NYU Langone Health

People needed

60

Starts

2026-09-01

Expected to finish

2031-09-01

Last updated by the study team

2026-08-05

Who can join

Age: 18 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• One of the following:
• A history of psoriasis as confirmed by a board-certified dermatologist OR
• A history of psoriatic arthritis as confirmed by a board-certified rheumatologist
• Age ≥ 18 \& < 90 years
• Able and willing to provide written informed consent for the study
• English-speaking unless a translated informed consent form is approved
• No previous antiplatelet or anticoagulant use for 14 days prior to enrollment

You may not qualify if…

• A prior history of a myocardial infarction, stroke/TIA, or occlusive peripheral arterial disease
• Chronic antiplatelet/anticoagulant use that is not able to be stopped at least 14 days prior to study enrollment
• Uncontrolled hypertension resting systolic blood pressure > 180 mm Hg or diabetes HbA1c > 10%
• Known active cancer receiving treatment
• Pregnancy
• Anemia (hemoglobin < 9 mg/dl) or thrombocytopenia (Platelet count <75), or thrombocytosis (Platelet count >600)
• A history of severe bleeding or bleeding disorders
• Active gastrointestinal ulcer
• Active pathological bleeding.
• Chronic kidney disease (CrCl < 30ml/min)
• Congestive heart failure
• Known hypersensitivity to or allergy to aspirin, clopidogrel, or any of the components of the study capsules
• History of aspirin-exacerbated respiratory disease or asthma induced by salicylates or NSAIDs
• Currently breastfeeding
• Persons of childbearing potential unwilling to use acceptable contraception during the study

Where it is running

• NYU Langone Health — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.